Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292095 | 0.79 | NOTUM (0.50) | NOTUMTAS1R3TAS1R1TAS1R2NAMPT | |
| SCHEMBL31292605 | 0.71 | NOTUM (0.49) | NOTUMMAPTNPC1RAB9AMEN1 | |
| SCHEMBL8192396 | 0.71 | NOTUM (0.61) | NOTUMTAS1R3TAS1R1TAS1R2NAMPT | |
| SCHEMBL861946 | 0.71 | MAOA (0.44) | NOTUMMAPTRIPK1NPC1RAB9A | |
| SCHEMBL24403117 | 0.68 | TDP1 (0.38) | NAMPTLMNAALOX15 | |
| SCHEMBL20609569 | 0.68 | ALDH1A1 (0.42) | NOTUMMAPTNAMPTRIPK1TAAR1 | |
| SCHEMBL28677772 | 0.68 | NOTUM (0.43) | NOTUMMAPTNAMPTRIPK1TAAR1 | |
| SCHEMBL10413341 | 0.68 | NOTUM (0.47) | NOTUMTAS1R3TAS1R1TAS1R2NAMPT | |
| SCHEMBL31575340 | 0.67 | DGAT1 (0.38) | KCNN4 | |
| SCHEMBL24606352 | 0.67 | MAOA (0.41) | NOTUMMAPTRIPK1HSP90AA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | NOTUM 4311/4885KCNN4 4456/4885MAPT 389/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | NOTUM 4311/4885KCNN4 4452/4885MAPT 383/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | NOTUM 4311/4885KCNN4 4456/4885MAPT 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.